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Cell-based regenerative medicine therapies require robust preclinical safety, eﬃcacy, biodistribution, and engraftment data prior to
clinical testing. To address these challenges, we have developed an imaging toolbox comprising multispectral optoacoustic
tomography and ultrasonography, which allows the degree of kidney, liver, and cardiac injury and the extent of functional
recovery to be assessed noninvasively in a mouse model of multiorgan dysfunction. This toolbox allowed us to determine the
therapeutic eﬀects of adoptively transferred macrophages. Using bioluminescence imaging, we could then investigate the
association between amelioration and biodistribution. Macrophage therapy provided limited improvement of kidney and liver
function, although not signiﬁcantly so, without amelioration of histological damage. No improvement in cardiac function was
observed. Biodistribution analysis showed that macrophages homed and persisted in the injured kidneys and liver but did not
populate the heart. Our data suggest that the limited improvement observed in kidney and liver function could be mediated by
M2 macrophages. More importantly, we demonstrate here the utility of the imaging toolbox for assessing the eﬃcacy of
potential regenerative medicine therapies in multiple organs.
1. Introduction
Cell-based regenerative medicine therapies (RMTs), which
include pluripotent stem cells, mesenchymal stromal cells,
and macrophages, have the potential to treat a variety of
human diseases. However, before these therapies can be rou-
tinely used in the clinic, accurate information regarding their
safety and eﬃcacy should be obtained from appropriate pre-
clinical models. It is also important to gain an understanding
of the therapeutic mechanisms of the RMTs, such as whether
their ability to ameliorate injury is dependent on their
engraftment in the damaged tissues. Issues which currently
prevent the generation of such data include (i) the limitations
associated with commonly used blood biomarkers of organ
injury, such as serum creatinine (SCr) and blood urea nitro-
gen (BUN) for renal function [1–5] and alanine aminotrans-
ferase for liver function [6–8]; (ii) the technical limitations in
repeated blood and urine sampling in small rodents; and (iii)
the diﬃculties associated with monitoring organ function in
small animal species longitudinally. The assessment of organ
injury in small rodents classically involves measurements of
serum or urine biomarkers, or histopathological analysis.
Since the latter is usually only undertaken at postmortem, it
fails to allow the progression of injury to be monitored in
the same animals longitudinally, requiring animals to be
culled at multiple time points, which is not in keeping with
the principles of the NC3Rs and also reduces the power of
the statistical tests. Furthermore, current methods make it
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diﬃcult to assess the safety, eﬃcacy, and therapeutic mecha-
nisms of cell-based RMTs in comorbid conditions where
more than one organ is aﬀected, such as in the cardiorenal
and hepatorenal syndromes [9–11].
In this current study, we set out to develop a multimodal
imaging strategy to monitor the function of the liver, kidney,
and heart longitudinally in BALB/c mice in a single imaging
session. We utilised multispectral optoacoustic tomography
(MSOT) to assess kidney and liver function and traditional
ultrasound (US) measurements to assess cardiac function.
MSOT is a technique which uses multiple excitation wave-
lengths to resolve speciﬁc sources of absorption using the
photoacoustic eﬀect, whether they are endogenous or exoge-
nous [12]. It relies on thermoelastic expansion which occurs
when energy from a laser capable of emitting light at a range
of wavelengths is absorbed by molecules within the tissues.
This causes electrons to move to an excited state, generating
heat and a resultant pressure wave which is detected by an
ultrasound detector. The speciﬁc absorption proﬁle of endog-
enous or exogenous molecules allows their identiﬁcation
within living animals in a minimally invasive manner [13].
We have previously described methods of monitoring kidney
or liver function using MSOT in models of chronic kidney
injury and acute liver injury [14, 15].
Here, we utilised an acute model of adriamycin- (ADR-
)-(doxorubicin-) induced multiorgan injury and assessed
organ function on days one and four post-drug administra-
tion in order to determine the extent of disease progression.
ADR is an anthracycline antibiotic which is clinically admin-
istered as a chemotherapeutic agent; however, its use is lim-
ited predominantly due to cardiotoxicity mediated through
a number of mechanisms. In rodents it can induce both
chronic and acute kidney injuries, as well as cardiac and
hepatic dysfunction [15–17]. To test the eﬀectiveness of this
MSOT-US bimodal imaging strategy for monitoring the
ameliorative potential of cell-based RMTs, after recording
the extent of kidney, liver, and cardiac dysfunction on day
one, mouse bone marrow-derived alternatively activated
(M2) macrophages (BMDMs) were administered intrave-
nously into BALB/c mice and their ability to improve the
function of the aforementioned organs was monitored on
day four and compared with a saline placebo. M2 BMDMs
were used in this study because previous reports have
already demonstrated that they can ameliorate kidney
injury, liver injury, and cardiac injury [18–20]. However, as
far as we are aware, M2 BMDMs have not previously been
assessed for their ability to ameliorate the injury of multiple
organs simultaneously. We then set out to assess the rela-
tionship between the biodistribution of the M2 BMDMs
and their ability to ameliorate injury in each of the three
organs by utilising bioluminescent imaging of M2 BMDMs
expressing luciferase.
2. Materials and Methods
2.1. Animals. Mice were purchased from Charles River, UK,
and were housed with ad libitum access to food and water.
All animal experiments were performed under a license
granted under the Animals (Scientiﬁc Procedures) Act 1986
and were approved by the University of Liverpool ethics
committee. Experiments are reported in line with the
ARRIVE guidelines.
2.2. Primary Macrophage Isolation. Primary bone marrow-
derived macrophages (BMDMs) were prepared as previ-
ously described [21]. Male BALB/c mice were used to isolate
BMDMs for the eﬃcacy study whereas for the biodistribution
study, mice with a mixed background (L2G85 mice bred to
wild-type FVB mice) expressing the CAG-luc-eGFP L2G85
transgene were used (FVB-Tg(CAG-luc,-GFP)L2G85Chco/J).
Brieﬂy, femurs and tibias of mice (8-10 weeks) were har-
vested and muscle tissue removed from the bones in a sterile
fume hood. Bone marrow was ﬂushed from the bones using a
sterile syringe with Dulbecco’s modiﬁed Eagle’s medium
(DMEM): F12 cell culture medium (Gibco) supplemented
with 10% foetal bovine serum, 2mM glutamine, and 1x peni-
cillin/streptomycin (Invitrogen). The bone marrow was sus-
pended in the medium before being passed through a cell
strainer (40μm) and then cultured in DMEM: F12 media
containing 20 ng/ml murine recombinant macrophage
colony-stimulating factor (MCSF-1). Bone marrow suspen-
sions were cultured at 37°C and 5% CO2, and medium was
replaced every other day. On day 7, macrophages were con-
sidered fully diﬀerentiated as determined by the expression
of both CD11b and F4/80 (BioLegend) by ﬂow cytometry.
Mature BMDMs were then polarised towards an M2-like
phenotype by the overnight addition of recombinant murine
interleukin- (IL-) 4 (20 ng/ml).
2.3. Induction of Organ Dysfunction. Male BALB/c mice
(8–10 weeks) received either adriamycin (20mg/kg, n = 11)
or saline (0.9%, n = 4) intraperitoneally (IP) on day 0. Adria-
mycin (doxorubicin hydrochloride, Tocris Bioscience) was
dissolved in warm saline (0.9%) to make a stock solution
(10mg/ml) before administration. Mice were weighed on a
daily basis to monitor their well-being, and mice which
received adriamycin were provided with a wet food diet.
2.4. Imaging Protocol. Imaging was carried out on days 1 and
4 under the same imaging session and using the following
protocol: mice were anaesthetised and fur was removed from
the torso by shaving and epilating. Mice were then imaged by
ultrasound to generate functional cardiac parameters. The
tail veins of mice were then cannulated, and mice moved to
the MSOT system and received ICG (Carl Roth, Germany)
for liver functional measurements. The catheter was ﬂushed
with saline before administration of IRDye800 carboxylate
(LI-COR) for functional kidney measurements. Mice were
then allowed to recover in a heat box before being returned
to their home cage. A schematic showing how the study
was carried out can be found in Figure 1. Results for MSOT
and ultrasound analyses are expressed as the change in each
parameter between days 1 and 4 in the study. Detailed
descriptions of each imaging protocol are provided below.
2.5. Assessment of Cardiac Function. Cardiac function was
assessed using the Prospect 2.0 ultrasound system (S-Sharp,
Taiwan). Mice were anaesthetised using isoﬂurane and oxy-
gen, and the mice were placed dorsally on a heated platform.
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Mice were ﬁxed in place during imaging using a surgical tape.
Ultrasound gel was applied to the chest area of the mice and
the ultrasound transducer positioned above the chest area.
The following parameters were measured: epicardial area
and endocardial area in the long-axis view, left ventricle
length, epicardial areas in the short-axis view, M-mode
images of both the long- and short-axis views in order to
measure heart rate, left ventricular interior diameter, and
wall thickness in both diastole and systole. These parameters
were used to calculate fractional shortening (FS), ejection
fraction (EF), stroke volume (SV), and cardiac output (CO).
2.6. Assessment of Liver Function. Liver function was assessed
using the inVision 256-TF MSOT imaging system (iThera
Medical, Munich). Immediately after assessment of cardiac
function, the mice were moved to the MSOT imaging system.
Prior to being placed into the system, the tail vein of the mice
was cannulated to allow injection of the optical imaging con-
trast agents during photoacoustic imaging. Mice were placed
in the system and allowed to acclimatise for 15 minutes prior
to recording data. Imaging focussed on the ischiatic vessels
close to the hips of the mice for detection of indocyanine
green (ICG) and its subsequent clearance. The following
parameters were used: an acquisition rate of 10 frames per
second (consecutive frames averaged to minimalise eﬀects
of respiration movement), with wavelengths of 700, 730,
760, 800, 850, and 900 nm being recorded. The half-life for
ICG in the blood is approximately 3 minutes. Six wavelengths
with averaging were used for ICG imaging to facilitate spec-
tral unmixing of MSOT data which improves image speciﬁc-
ity. The temporal resolution of this imaging protocol is less
than 10 s, which is suﬃcient to characterise a half-life which
is in the order of minutes. Data were recorded for 3 minutes
prior to intravenous (IV) injection of ICG (40nmol, 100μl)
over a 10 s period. Data were reconstructed using a model
linear algorithm (View MSOT software) and multispectral
processing using linear regression for ICG, deoxy- and oxy-
haemoglobin spectra to resolve the signal for the ICG dye.
Regions of interest drawn around the ischiatic vessels of each
mouse were used to quantify the ICG dye signal (as mean
pixel intensity) in the vessels of the mice. These data were
used to calculate the area under the clearance curve (AUC).
Data were expressed as the change in ICG AUC in each indi-
vidual mouse between days 1 and 4 (ΔICG AUC).
2.7. Assessment of Kidney Function. Kidney function was
assessed utilising a similar method as the assessment of liver
function. After liver function assessment, the catheter was
ﬂushed with a small amount of saline. Data were recorded
using the following parameters: wavelengths of 775 and
850 nm and an acquisition rate of 10 frames per second (con-
secutive frames averaged). The imaging protocol for kidney
imaging diﬀered from the liver in that only 2 wavelengths
with averaging were used for the former, enabling the tempo-
ral resolution to be increased by a factor of 3. This was neces-
sary because of the faster kinetics of IRDye [15], compared
with ICG, and because 2 ROIs were analysed to assess kidney
function, whereas just one ROI was needed to assess liver
function. Data was recorded for 3 minutes prior to the injec-
tion through the tail vein catheter of IRDye 800 carboxylate
(20nmol, 100μl) over a period of 10 s. Data was reconstructed
using a model linear algorithm and a diﬀerence protocol
(775nm–850nm) to resolve the signal for the IRDye. Regions
of interest were drawn around the renal cortex and the renal
papilla/pelvis region of the right kidney in each mouse to
quantify the IRDye signal in the kidney. Regions of interest
were drawn on an individual animal basis to reﬂect the renal
cortex and renal papilla/pelvis based on the visible IRDye sig-
nal resolved using multispectral processing. The mean pixel
intensity data were used to calculate the AUC of both the renal
cortex and papilla/pelvis. Data were expressed as the change in
the ratio between the AUC of the cortex and the AUC of the
pelvis regions between days 1 and 4 (ΔAUC C :P).
2.8. Therapeutic Cell Administration. M2-like primary
BMDMs were administered to mice which received adriamy-
cin (n = 6) on day 1 immediately after cardiac, hepatic, and
renal imaging. BMDMs were harvested from low-adherence
ﬂasks (Corning) after maturation and polarisation by gentle
agitation and scraping. Cells were then counted and sus-
pended to a concentration of 107 cells/100μl saline. After the
mice were removed from the MSOT imaging system, 100μl
of the cell suspension was administered via the tail vein can-
nula and mice were allowed to recover in a heat box before
being returned to their home cage. Mice which did not receive
BMDMs received 100μl saline via the tail vein catheter.
2.9. Quantiﬁcation of Serum Biomarkers. On day 4, mice
were culled using an increasing concentration of CO2 and
Day 1 Day 4Day 0
Mice receive
ADR or saline IV
Mice receive 107 M2
BMDMs or saline IV 
MSOT and
US imaging
MSOT and
US imaging
 Mice are culled and blood
and organs are collected 
Figure 1: Schematic showing the experimental protocol.
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exsanguinated by cardiac puncture. Blood was allowed to
clot at room temperature before centrifugation to isolate
the serum.
Blood urea nitrogen (BUN, QuantiChrom Urea Assay
Kit, BioAssay Systems), serum creatinine (SCr, serum creati-
nine detection kit, ARBOR ASSAYS), and alanine amino-
transferase activity (ALT, Thermo Fisher) were quantiﬁed
according to the manufacturer’s instructions in a 96-well
plate and were read using a FLUOstar Omega microplate
reader (BMG LABTECH).
2.10. Histopathological Analysis. Kidney and liver tissues
were ﬁxed in 4% paraformaldehyde (4°C) for 24 hours before
being washed in PBS, dehydrated with increasing concentra-
tions of ethanol, and subsequently embedded in paraﬃn.
The kidneys were sectioned in order to obtain two symmet-
rical halves, to include the cortex and medulla extending to
the renal pelvis. For the liver, the large lobe was collected
for analysis. Tissue sections were cut (5μm) and were
stained with haemotoxylin and eosin (HE) and periodic
acid-Shiﬀ (PAS) by standard methods. Kidney injury was
scored 0-5 on 10 consecutive 200x microscopic ﬁelds in
the outer stripe of the outer medulla and cortex on PAS-
stained slides adapting the method described from Wang
and colleagues [22]. For the liver, histological sections were
assessed semiquantitatively for degeneration and necrosis
following a semiquantitative scale representative for the sec-
tion area involved (0 = 0%; 1 = 1-25%; 26-50%; 51-75%; 76-
100%). Veterinary pathologist was blinded in regard to the
experimental groups.
2.11. Determining Cellular Biodistribution. To determine cel-
lular biodistribution by bioluminescence imaging, male
BALB/c mice (8–10 weeks) were used. The same adriamycin
and macrophage dosing schedule was used as in the previous
study: mice received either 20mg/kg adriamycin IP (n = 6) or
saline IP (n = 6). 24 hours later, all mice received IV injec-
tions of 107 PMDMs isolated from mice expressing the
CAG-luc-eGFP L2G85 transgene. All mice received luciferin
(1.5mg/kg, IP) before being imaged using an IVIS Spectrum
In Vivo Imaging System (PerkinElmer). Mice were imaged in
both dorsal and ventral positions using an automatic expo-
sure time before being sacriﬁced. Organs were then dissected
and imaged using the same protocol. The remaining mice
were returned to their home cages until day 4 postadriamycin
administration (the study endpoint) when they were imaged
as previously described.
2.12. Statistical Analysis. Statistical analyses were carried out
using Origin software. One-way ANOVA was used for com-
parison of two groups, and one-way ANOVA followed by
Tukey analysis was used to compare multiple groups. Results
were determined to be signiﬁcant when P < 0 05. To assess
whether correlations between results were signiﬁcant, Pear-
son’s correlation coeﬃcient was calculated.
3. Results
3.1. Use of High-Frequency Ultrasonography to Investigate the
Eﬀect of BMDMs on Cardiac Function in ADR-Dosed Mice.
High-frequency ultrasonography was used to determine
whether cardiac function was aﬀected in treated (ADR+
BMDM), injured (ADR), and control mice (Figure 1) by
measuring the following functional parameters: fractional
shortening (FS), ejection fraction (EF), stroke volume (SV),
and cardiac output (CO). The mean ΔFS (Figure 2(a)) and
ΔEF (Figure 3(b)) was decreased in the ADR and ADR+
BMDM groups when compared to uninjured controls, but
not signiﬁcantly so. However, there were signiﬁcant changes
in ΔCO (Figure 2(c)) and ΔSV (Figure 2(d)), with both
parameters being signiﬁcantly reduced in the ADR and
ADR+BMDM groups compared to healthy controls.
3.2. Use of MSOT to Investigate the Eﬀect of BMDMs on Renal
Function in ADR-Dosed Mice.MSOT was used to assess renal
function in healthy mice, those which received ADR and
those which received ADR+BMDMs, on days 1 and 4 follow-
ing ADR administration (Figure 1). Uninjured control mice
lost approximately 2.5% of their body weight over the 4-day
time course of the experiment whereas animals that received
ADR had a signiﬁcant reduction in body weight (18%), irre-
spective of whether they were administered macrophages
(Supplementary Figure 1, Table 1). MSOT was used to
assess kidney function by measuring the renal clearance of
the near-infrared dye, IRDye 800 carboxylate (IRDye),
which is exclusively ﬁltered by the kidney (Supplementary
Figure 2). Regions of interest were drawn around the
corticomedullary region and the renal pelvis to generate
intensity data for quantitative measurements (Figure 4(a)).
We observed that the typical clearance curves of IRDye on
day 4 in both the cortex and pelvis were changed in
animals with ADR-induced kidney injury when compared
to those in healthy control mice (Figures 4(b) and 4(c)).
The clearance kinetics of IRDye in mice after ADR injury
and BMDM administration were also altered compared
to the healthy controls (Figure 4(d)). For quantitative
analysis of the changes observed in each individual animal,
IRDye clearance data were expressed as the diﬀerence in
the Cortex : Pelvis AUC between the measurements taken
on days 1 and 4 (ΔAUC C :P). There was a signiﬁcant
increase in the ΔAUC C :P between the healthy controls
and the ADR group, but not between the healthy controls
and the ADR+BMDM group (Figure 4(e)). In addition,
we assessed the renal function using classical markers of
blood urea nitrogen (BUN) and serum creatinine (SCr)
on day 4 (Figures 4(f) and 4(g), respectively). BUN was
signiﬁcantly elevated in the ADR and ADR+BMDM groups
compared to healthy controls, whereas there were no
signiﬁcant changes in SCr between all three treatment
groups. Furthermore, there was a signiﬁcant correlation
between the AUC C : P and day 4 BUN measurements
(Figure 4(h), P = 0 013, R2 = 0 39).
3.3. Use of MSOT to Investigate the Eﬀect of BMDMs on
Hepatic Function in ADR-Dosed Mice. We assessed the liver
function with MSOT as previously described [14] by measur-
ing the clearance of indocyanine green (ICG) which is exclu-
sively eliminated from the blood by the liver. Representative
MSOT snap shot images illustrate the change in ICG signal in
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the ischiatic vessel (Figure 3(a)). The blue to red colour scale
represents MSOT mean pixel intensity for the resolved
IRDye signal scaled to the maximum pixel intensity. Plotting
of the signal intensities over time showed that ICG clearance
was delayed both in the ADR+BMDM and the ADR groups
compared to the saline group (Figures 3(b)–3(d)). To inves-
tigate the ameliorative potential of BMDMs on liver function,
we determined the change in AUC for ICG between days 1
and 4 in each individual mouse (ΔICG AUC) (Figure 3(e)).
There was a signiﬁcant elevation in ΔICG AUC in the ADR
group compared to healthy controls, but not between con-
trols and ADR+BMDM groups, nor between the ADR and
ADR+BMDM groups (Figure 3(e)). Alanine aminotransfer-
ase (ALT) was signiﬁcantly elevated in the sera of the ADR
and ADR+BMDM groups compared to the controls on day
4 (Figure 3(f)) and correlated signiﬁcantly with ICG AUC
(P = 0 0009, R2 = 0 59) (Figure 3(g)). To investigate the rela-
tionship between cardiac, kidney, and liver injury, we plotted
cardiac output together with the MSOT data for kidney and
liver function on a 3D graph. This shows the relationship
between CO, kidney, and liver function for each animal
(Supplementary Figure 3).
3.4. BMDMs Failed to Ameliorate ADR-Induced Histological
Damage in the Kidney and Liver. The functional data from
the MSOT analyses suggested that BMDMs had a tendency
to improve renal and hepatic function in ADR-dosed mice
but did not improve cardiac function. To investigate whether
the apparent improvement in renal and hepatic function was
associated with an amelioration of tissue damage, histological
analysis of the liver and kidneys of mice was carried out at the
study endpoint. Kidney sections were assessed for the pres-
ence of intratubular protein casts and ﬂattened tubular epi-
thelium and liver sections for hepatocellular degeneration
and necrosis. There was a signiﬁcant diﬀerence between
healthy and ADR-injured animals, but in contrast to the
functional data, administration of BMDMs failed to improve
the extent of histological damage in the kidney or liver. His-
tologically, the kidneys of control mice showed no evidence
of injury (Figure 5(a)) whereas the kidneys of ADR mice
had intratubular protein casts and ﬂattening of tubular
epithelial cells (Figure 5(b), arrow) regardless of BMDM
administration. Likewise, the livers of control mice showed
no signs of injury (Figure 5(c)) whereas ADR and ADR+
BMDM mice showed evidence of hepatocellular degenera-
tion (Figure 5(d)(1)) and necrosis (Figure 5(d)(2)). Histolog-
ical scoring in both the kidney and liver showed that control
mice had no evidence of histological damage whereas both
the ADR and ADR+BMDM groups showed varying degrees
of injury (Figures 5(e) and 5(f), respectively).
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Figure 2: Cardiac parameters as measured by ultrasound. Fractional shortening (a), ejection fraction (b), cardiac output (c), and stroke
volume (d) were quantiﬁed. Each parameter is represented as the change in the parameter between days 1 and 4 in each mouse. Each data
point represents an individual mouse. ∗∗P < 0 01, ∗∗∗P < 0 001.
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Figure 3: Representative images showing a typical cross section of a mouse as obtained by the MSOT both prior to, immediately post-, and 1
minute post-ICG administration (a). Clearance kinetics on day 4 of ICG from a typical healthy mouse (b), an ADR-treated mouse (c), and an
ADR+BMDMmouse (d) from a single ischiatic vessel’s region of interest. The blue to red colour scale represents MSOT mean pixel intensity
for the resolved ICG signal scaled to the maximum pixel intensity. The change in the mean ICG AUC between days 1 and 4 in all mice is
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minutes post-IRDye administration; cortex and medullary regions of interest are shown (a). The blue to red colour scale represents MSOT
mean pixel intensity for the resolved IRDye signal scaled to the maximum pixel intensity. Clearance kinetics on day 4 of IRDye 800
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0.755, and 2.866). Serum BUN (f) (mean 24.7, 43.4, and 41.1mg/dl) and SCr (g) levels were quantiﬁed on day 4 in each mouse. The
correlation between the cortex : pelvis AUC and blood urea nitrogen on day four is shown in (h). Each data point represents an individual
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3.5. Bioluminescence Imaging Shows that BMDMs
Accumulated in the Kidneys and Liver following ADR-
Induced Injury, but Not in the Heart. In order to investigate
the eﬀect of organ injury on BMDM distribution, mice were
imaged on the same day, or 3 days after administration of
luciferase+BMDMs, which corresponded to the 1st and 4th
day following saline or ADR administration. Biolumines-
cence imaging showed that on day 1, cells were mostly in
the lungs of both control and ADR animals. By day 4,
BMDMs were no longer detectable in the controls but had
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Figure 5: Histological analyses from both the kidney and liver. Histological analyses show sections from typical sections of a kidney from a
healthy mouse (a), the kidney of a mouse which had received adriamycin (b), the liver of a healthy mouse (c), and the liver of a mouse which
had received adriamycin (d1, d2). All organs were collected on day 4 of the study and were stained with haematoxylin and eosin. (a) and (b)
scale bar = 100 μm. (c) and (d) scale bar = 50 μm. No evidence of injury is observed in (a) or (c). (b) shows evidence of intratubular protein
casts and ﬂattening of the tubular epithelium (arrow). (d1) shows evidence of hepatocellular degeneration (arrow) and (d2) shows evidence of
necrosis with evidence of pale eosinophilic substance. Histological scoring for the kidney and liver is shown (e and f, respectively). Each data
point represents an individual animal.
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a widespread distribution in the ADR group (Figures 6(a)
and 6(b)). Given the poor spatial resolution of biolumines-
cence imaging, it was not possible to determine which organs
the BMDMs had populated in the ADR group at day 4.
Therefore, immediately after in vivo imaging on day 1, three
animals were immediately sacriﬁced to quantify the biodistri-
bution of BMDMs in the major organs ex vivo, with the
remaining three mice being sacriﬁced on day 4. Similarly to
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Figure 6: All mice received 107 primary bone marrow-derived macrophages which expressed luciferase via tail vein administration. Whole-
body images of typical mice treated with either saline or adriamycin on both days 1 (a) and 4 (b). Ex vivo bioluminescence images from typical
saline (c, e) and adriamycin- (d, f) treated mice on both days 1 (c, d) and 4 (e, f). Individual scales are shown on the right of each image. Each
image shows the liver, kidneys, heart, lungs, and spleen from an individual mouse. Scales for all ex vivo images are identical, as are scales for all
whole-body images.
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the in vivo data, ex vivo analysis of organs on day 1 showed
no obvious diﬀerence between control and ADR mice, with
most BMDMs being in the lungs and some detected in the
spleen (Figures 6(c) and 6(d)). By day 4, BMDMs could only
be detected in the lungs of control animals but were present
in the lungs, spleen, kidneys, and liver of ADR animals.
BMDMs were not detected in the hearts of control or ADR
animals (Figures 6(e) and 6(f)).
We measured the total ﬂux from the individual organs
ex vivo to quantify the diﬀerences in organ biodistribution
between the treatment groups and time points (Figure 7).
The total ﬂux from the heart, lungs, and spleen decreased
between days 1 and 4 in both the control and ADR mice
(Figures 7(a)–7(c)). The same trend was observed for the
liver and kidney in the controls, with total ﬂux decreasing
between days 1 and 4. On the other hand, in the ADR mice,
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Figure 7: Quantiﬁed ex vivo bioluminescent results from organs of mice that received either saline or adriamycin on both days 1 and 4. Data
is shown for the heart (a), the lungs (b), the spleen (c), the liver (d), and the mean of both kidneys (e). Each bar represents the mean of 3
individual animals. ∗P < 0 05.
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total ﬂux increased signiﬁcantly in the liver and kidneys
between days 1 and 4 (Figures 7(d) and 7(e)).
4. Discussion
In the current investigation, cardiac function was measured
by ultrasonography alongside hepatic and renal function
by MSOT under the same anaesthesia session. This allowed
us to determine the function of 3 separate organs utilising a
multimodal imaging approach. The cardiac measurements
taken easily and quickly with the ultrasound software
revealed that there were no signiﬁcant changes in fractional
shortening or ejection fraction between days 1 and 4 in the
ADR and ADR+BMDM groups when compared to the
healthy mice. However, signiﬁcant decreases in cardiac out-
put and stroke volume between days 1 and 4 were detected
when comparing the saline-treated mice to those which
received adriamycin, regardless of the addition of M2
BMDMs. This suggests that a single dose of adriamycin sig-
niﬁcantly reduces cardiac function between days 1 and 4 of
this study; however, the addition of BMDMs as a RMT shows
no beneﬁcial eﬀect on cardiac function.
We have previously used MSOT to monitor renal func-
tion in a mouse model of adriamycin-induced chronic kidney
disease by measuring the clearance kinetics of IRDye [15].
The two parameters used in this earlier study, which focussed
on the chronic stage of renal injury, were the Tmax delay and
the exponential decay time of the IRDye in the renal cortex,
which were measured at week 5 following ADR dosing,
when the nadir of acute renal injury had passed. However,
in the current study, which focussed on the acute phase of
adriamycin-induced injury, these parameters were not
appropriate because many animals did not display an IRDye
“peak” in the pelvis, nor an exponential decay in the renal
cortex. Therefore, we considered that the most appropriate
parameter in this case would be the ratio of the AUC of the
cortex and pelvis kinetic curves (AUC C : P), as this measure-
ment reﬂects both impaired clearance through the cortex and
delayed accumulation in the pelvis and could be measured in
all animals. A single dose of adriamycin caused a signiﬁcant
reduction in kidney function when compared to healthy mice
over a 4-day period. Administration of M2 BMDMs 1 day
after adriamycin administration resulted in a nonsigniﬁcant
reduction in kidney function when compared to control
mice. The AUC C : P showed a strong positive correlation
with a more traditional biomarker of kidney injury, BUN,
which reinforces the utility of AUC C : P as a measure of
kidney function. There were, however, no diﬀerences
between the mean BUN measurements in mice which
received adriamycin alone and those which received adria-
mycin and M2 BMDMs. SCr was not signiﬁcantly diﬀerent
between any of the groups, which highlights the lack of sen-
sitivity of this biomarker for indicating renal function in
rodents. Histological analyses of the kidneys showed evi-
dence of intratubular protein casts and ﬂattening of tubular
epithelium in mice which received adriamycin, irrespective
of whether they were administered BMDMs or not. There-
fore, although MSOT showed that the M2 BMDMs appeared
to cause a subtle improvement in renal function, there was
no corresponding improvement in histological damage or
BUN levels. A study by Lu and colleagues demonstrated
that M2 macrophages reduce inﬂammatory inﬁltrates in
adriamycin-induced nephropathy; however, macrophages
were not administered until 5 days after adriamycin admin-
istration and biomarker analyses not carried out until day 28
[23]. It is possible in this current study that analysis of kidney
function at later time points than day 4 may have yielded
more signiﬁcant improvements in function. Wang and
colleagues studied the eﬀect of M0, M1, and M2 activated
macrophages in a mouse model of chronic adriamycin
nephropathy [24]. These authors found that by 4 weeks,
M0 macrophages had no eﬀect on renal injury, while M1
macrophages promoted histological damage, and M2 macro-
phages signiﬁcantly ameliorated tubular and glomerular
injury [24]. By contrast, we failed to observe any ameliorative
eﬀects of the M2 macrophages on tissue damage, but this
may have been because our analysis was performed at 4 days,
rather than at 4 weeks. Consistent with our current study,
Wang and colleagues showed that M2 macrophages traf-
ﬁcked to inﬂamed kidneys. In addition, they provided evi-
dence that the exogenous M2 macrophages ameliorate
injury by reducing the inﬁltration of resident macrophages,
thereby reducing inﬂammation.
In the current study, the clearance of ICG from the blood
of mice was used as a measure of liver function. ICG is a
ﬂuorescent cyanine dye which is used clinically in a number
of diagnostic procedures including measurement of car-
diac output, liver blood ﬂow, ophthalmic angiography, and
hepatic function [25–27]. It absorbs in the near-infrared
region which makes it an ideal optoacoustic contrast agent.
This, combined with the fact that ICG is microsomally meta-
bolised in the liver and cleared through the hepatobiliary
route, makes it an ideal agent for determination of liver
function withMSOT. Using the ICG AUC, we show here that
there was no change in liver function in healthy mice
between days 1 and 4 whereas mice which received adriamy-
cin had a signiﬁcantly decreased liver function in the same
time window. Liver function was also decreased between days
1 and 4 in mice which received adriamycin and M2 BMDMs,
but not signiﬁcantly so when compared to healthy mice. This
suggests that a single high dose of adriamycin reduces liver
function while the addition of M2 BMDMs has a beneﬁcial
eﬀect on the function of the liver. The ICG AUC on day 4
of the study correlates strongly and signiﬁcantly with serum
ALT levels, reinforcing the utility of ICG AUC as a functional
liver parameter. Histological analyses showed no evidence of
liver injury in healthy mice while hepatocellular degeneration
and necrosis were observed in all mice which received adria-
mycin. Again, much like the kidney histopathology and bio-
marker analysis, there were no diﬀerences in ALT or liver
histology between mice which received adriamycin alone
and those which received adriamycin and the M2 BMDMs.
A previous work by Thomas and colleagues found that exog-
enous unpolarised BMDMs had a beneﬁcial eﬀect on mice
with carbon tetrachloride-induced liver injury through the
recruitment of matrix metalloproteinase- (MMP-) producing
host cells into the liver [28]. This in turn increased host mac-
rophage recruitment and elevated IL-10 and MMP levels.
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The study also showed modest but signiﬁcant increases in
serum albumin, suggesting liver regeneration [28]. The
results we present here also suggest a modest improve-
ment in liver function as measured by MSOT, albeit insig-
niﬁcantly. It should be noted that the eﬀect of M2 BMDMs
on adriamycin-induced liver injury has not previously
been investigated.
The aforementioned multimodal imaging strategy can
monitor changes in the functions of the liver, kidney, and
heart and identify potential eﬃcacy of M2 BMDMs as a
RMT. To investigate the relationship between biodistribution
of the M2 BMDMs and any therapeutic eﬀect, we adminis-
tered M2 BMDMs expressing ﬁreﬂy luciferase which allowed
the luminescent imaging and quantiﬁcation of cells in the
mice and organs (three on day 1 and three on day 4). At
day 1, we observed no diﬀerence in luminescence distribu-
tion between both groups of mice, with signals only present
in the lungs and spleen after IV cell administration. This pat-
tern of biodistribution has been reported widely after IV
administration of cells [29]. However, on day 4 of the study,
the biodistribution of the cells in saline or adriamycin-dosed
mice had changed dramatically. In the saline-treated mice,
there remained only a weak luminescent signal in the lungs,
indicating that the cells rapidly die after IV administration.
However, in mice which received adriamycin, this was not
the case; luminescence was detected over the whole body of
the mouse when imaged in vivo and in the liver, kidneys,
lungs, and spleen, but not the heart, when imaged ex vivo.
While the luminescent signal intensity decreased from days
1 to 4 in the lungs and spleen, it was still observable. On
the other hand, the signal intensity in the liver and kidneys
was signiﬁcantly elevated between days 1 and 4. Of note,
the total ﬂux in the whole-body images on day 4 in ADR-
treated mice appeared greater than on day 1.
5. Conclusions
We show that ADR-induced impairment of liver and kidney
function measured with MSOT correlates well with tradi-
tional serum biomarkers of injury. We also show that the
addition of M2 BMDMs improves kidney and liver function,
albeit not signiﬁcantly so, but has no beneﬁcial eﬀects on car-
diac function. Bioluminescence imaging showed that M2
BMDMs persisted in the kidneys and liver of ADR-dosed
mice but were not detected in the heart. It is not clear if the
presence of M2 BMDMs in the kidneys and liver was related
to the limited functional improvement that was observed in
those organs. Although we do not show any signiﬁcant
improvement in organ function as measured by MSOT, we
do however describe and demonstrate the utility of a nonin-
vasive multimodal imaging toolbox for assessing the eﬃcacy
and biodistribution of a potential regenerative therapy.
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